The Scottish Medicines Consortium (SMC) have issued final advice recommending the approval of Boehringer Ingelheim’s Trajenta with insulin to treat adults with type 2 diabetes to improve glycaemic control. The recommendation follows a Health Technology Appraisal accepting Trajenta (linagliptin) for treatment in combination with insulin with or without metformin, when insulin alone, with diet and
The Clinigen Group have announced that they are acquiring Idis for £225 million. The acquisition with Idis, an unlicensed medicines supplier, will make the Clinigen Group the global leader in unlicensed medicines. The ethical unlicensed supply market is estimated to be worth in excess of $5bn. Idis supplies unlicensed medicines predominantly on an exclusive basis
Drug makers who do not offer any genuine value will “disappear” over the next decade, according to Roche’s chief executive, Severin Schwan. Speaking at the Financial Times’ Pharmaceutical and Biotechnology conference in London, Schwan described a three-segment model with highly-innovative companies on one side and generics on the other. Schwan stated that the number of
